Screener
Abbott ABT Established Pharmaceuticals — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Net Sales to External Customers / Three Months Ended June 30, 2026 | Net Sales to External Customers / Three Months Ended June 30, 2025 | Cost of Products Sold / Three Months Ended June 30, 2026 | Cost of Products Sold / Three Months Ended June 30, 2025 | Research and Development / Three Months Ended June 30, 2026 | Research and Development / Three Months Ended June 30, 2025 | Selling, General, and Administrative / Three Months Ended June 30, 2026 | Selling, General, and Administrative / Three Months Ended June 30, 2025 | Operating Earnings / Three Months Ended June 30, 2026 | Operating Earnings / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Established Pharmaceuticals | $1,499 | $1,383 | $(650) | $(631) | $(48) | $(43) | $(419) | $(363) | $382 | $346 |
| Nutritional Products | 2,144 | 2,212 | (1,148) | (1,155) | (54) | (54) | (574) | (585) | 368 | 418 |
| Diagnostic Products | 3,092 | 2,173 | (1,532) | (1,224) | (268) | (154) | (793) | (423) | 499 | 372 |
| Medical Devices | 5,853 | 5,369 | (1,925) | (1,758) | (470) | (430) | (1,489) | (1,385) | 1,969 | 1,796 |
| Total | $12,588 | $11,137 | $(5,255) | $(4,768) | $(840) | $(681) | $(3,275) | $(2,756) | $3,218 | $2,932 |
| Other | 5 | 5 | ||||||||
| Net sales | $12,593 | $11,142 | ||||||||
| Corporate functions and plan benefit costs | (45) | (65) |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's established pharmaceuticals — R&D?
- Abbott (ABT) reported established pharmaceuticals — R&D of $48M in Q2 2026.
- How has Abbott's established pharmaceuticals — R&D changed year-over-year?
- Abbott's established pharmaceuticals — R&D increased by 11.6% year-over-year, from $43M to $48M.
- What is the long-term trend for Abbott's established pharmaceuticals — R&D?
- Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — R&D has grown at a -1.8% compound annual growth rate (CAGR), from $186M to $176M.
- What does established pharmaceuticals — R&D mean?
- This metric tracks the investment in scientific research, clinical trials, and product development specifically for the established pharmaceuticals segment. It reflects the company's commitment to sustaining its product pipeline and maintaining competitive relevance. Consistent investment is essential for long-term growth in the pharmaceutical sector.
Ask your AI about Abbott's established pharmaceuticals — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude